CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
G03-52-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04171115
NCT04171115Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

Alachua Government Services, Inc.·interventional·Posted Nov 20, 2019·Updated Oct 4, 2024

In Brief

A Phase 1 clinical trial evaluating G03-52-01 and Placebo for Healthy. Completed, enrolled 40 participants across 1 site.

Detailed Summary

A Phase 1, randomized, double-blind, placebo-controlled dose escalation trial of four dose cohorts of 10 subjects (1: 10mg, 2: 25mg, 3: 50mg, 4: 100mg).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 20, 2019
Enrollment StartJun 1, 2020
Primary CompletionAug 20, 2022
Study CompletionApr 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.6 years ago

Interventions

G03-52-01drug

G03-52-01 administered intramuscularly

Placebodrug

Placebo administered intramuscularly